NeuroSearch A/S

NEUR 
(NasdaqOMXC) 
 
dkk 3.50 <%= Resources.Global.txtUp %>
Updated 09:57:06
Change % 0.57% Stock price increasing
Change 0.02 Stock price increasing
Volume 2,425
High DKK 3.50
Low DKK 3.48
Open DKK 3.48
ISIN DK0010224666
Prev close DKK 3.48
# of shares 24.55M
Market cap 85.94M DKK
Intraday

NeuroSearch A/S
Market is open (until 16:00) - Delayed 15 min
 
Price development Latest 1 week 1 month 3 months 6 months 1 year
 
  3.50 1.2% Stock price increasing 2.3% Stock price increasing 0.0% Stock price unchanged -3.8% Stock price decreasing 48.9% Stock price increasing
Key Figures (m DKK)
Turnover
EBIT
Net Profit
Equity
Balance
2016
0
-6,300
22,815
71,383
79,421
2015
0
-6,488
-5,538
72,400
78,594
2014
0
-13
-8
78
84
2013
29
-10
12
88
92
2012
121
-290
-276
81
208
2011
0
-383
-678
321
841
2010
69
-328
-259
994
1,392
2009
85
-356
-287
1,174
0
2008
67
-366
-382
0
0
2007
115
-253
-268
1,121
0
Powered by TradingView

Related

Latest 1 week 1 month 3 months 6 months 1 year
YTD
 
Competitors Open
 
Vivus Inc 0.78 -8.4% Stock price decreasing -21.3% Stock price decreasing -35.2% Stock price decreasing -22.2% Stock price decreasing -29.3% Stock price decreasing -32.4% Stock price decreasing
 
H Lundbeck A/S 379.80 -3.5% Stock price decreasing 5.5% Stock price increasing 1.0% Stock price increasing 12.9% Stock price increasing 71.3% Stock price increasing 32.2% Stock price increasing

Company profile

NeuroSearch is a biopharmaceutical company specializing in central nervous diseases (CNS). The company has two businesses: Specialty Pharma, focusing on completing the development and marketing of their first product; Huntexil against Huntington's disease. The second business NsDiscovery, manages early drug discoveries. The drug Tesofensine against obesity is also ready for clinical phase III and NeuroSearch seeks a partner for completion of development. Main risk factor for drug development is financial risk. The company has several drug discovery- and development collaborations with major pharmaceutical companies such as Abbott, Eli Lilly and Janssen Pharmaceuticals. The cooperation entitles NeuroSearch to premarketing milestone payments on each compound developed and potentially royalties if the drug is commercialized.

Peers

Instruments Last Change  
Vivus Inc 0.778 0.0% Stock price unchanged
98,99,67,85,45,54,27,27,0,19
Lundbeck A/S 379.80 -1.1% Stock price decreasing
100,65,49,34,31,31,25,25,12,1

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
19 October 2017 11:42:33
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20171017.1 - EUROWEB5 - 2017-10-19 12:42:33 - 2017-10-19 11:42:33 - 1000 - Website: OKAY